Related Experiment Video
Updated: Aug 12, 2026
09:31
Assessing Replication and Beta Cell Function in Adenovirally-transduced Isolated Rodent Islets
Published on: June 25, 2012
Insulin-like effects of vanadium: basic and clinical implications
I Goldwaser1, D Gefel, E Gershonov
1Department of Biological Chemistry, The Weizmann Institute of Science, Rehovot, Israel.
Journal of Inorganic Biochemistry
|July 8, 2000
Summary
Vanadium exhibits insulin-like effects, showing promise for diabetes treatment by normalizing blood glucose. New organically chelated vanadium compounds offer reduced toxicity and enhanced potency.
Area of Science:
- Biochemistry
- Endocrinology
- Trace Element Research
Background:
- Mammalian cells contain vanadium, a trace element with no established physiological role.
- Vanadate inhibits Na+,K+-ATPase; vanadium mimics insulin's metabolic effects.
- Vanadium acts independently of the insulin receptor in key metabolic tissues.
Purpose of the Study:
- To investigate the antidiabetic potential of vanadium.
- To explore vanadium's insulin-mimetic properties in diabetic models.
- To review novel organically chelated vanadium compounds for improved therapeutic outcomes.
Main Methods:
- Review of studies on vanadium's effects on Na+,K+-ATPase and insulin signaling.
- Analysis of vanadium's efficacy in streptozotocin-induced diabetic rats and type II diabetic rodents.
- Evaluation of organically chelated vanadium compounds for potency and toxicity.
Main Results:
- Vanadium normalizes blood glucose in diabetic rodents and corrects hyperglycemia-related deficiencies.
- Therapeutic effects observed in type II diabetic rodents resistant to insulin.
- Organically chelated vanadium compounds demonstrate higher potency and lower toxicity than vanadium salts.
Conclusions:
- Vanadium holds significant therapeutic potential for diabetes management.
- Overcoming vanadium toxicity is crucial for clinical application.
- Novel organically chelated vanadium compounds represent a promising advancement in vanadium-based antidiabetic therapy.
More Related Videos
08:22Combined Intravital Microscopy and Contrast-enhanced Ultrasonography of the Mouse Hindlimb to Study Insulin-induced Vasodilation and Muscle Perfusion
Published on: March 20, 2017
07:30Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
Published on: May 10, 2018
Related Concept Videos
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:26Diabetes Mellitus: Introduction
Diabetes mellitus consists of chronic metabolic disorders characterized by persistent hyperglycemia. This elevated blood glucose results from defects in insulin secretion, impaired insulin action, or both. Insulin, produced by pancreatic β-cells, is essential for maintaining glucose homeostasis by facilitating cellular glucose uptake for energy or storage. Disruptions in insulin production or function lead to glucose accumulation in the bloodstream, causing the clinical features and long-term...
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
01:19Type I Diabetes III: Clinical Manifestations
Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
01:25Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...